v3.26.1
Condensed Consolidated Statement of Changes in Stockholders’ Equity - Unaudited - USD ($)
$ in Thousands
Total
Class A Common Stock
Class B Common Stock
Total vTv Therapeutics Inc Stockholders’ Equity (Deficit)
Common Stock
Class A Common Stock
Common Stock
Class B Common Stock
Additional Paid-in Capital
Accumulated Deficit
Noncontrolling Interest
Beginning balance, shares (in shares) at Dec. 31, 2024         2,612,257 577,349      
Beginning balance at Dec. 31, 2024 $ 14,301     $ 12,199 $ 26 $ 6 $ 311,885 $ (299,718) $ 2,102
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income (loss) attributable to vTv Therapeutics Inc. (5,092)     (5,092)       (5,092)  
Share-based compensation 813     813     813    
Net loss attributable to noncontrolling interest (1,125)               (1,125)
Ending balance, shares (in shares) at Mar. 31, 2025         2,612,257 577,349      
Ending balance at Mar. 31, 2025 8,897     7,920 $ 26 $ 6 312,698 (304,810) $ 977
Beginning balance, shares (in shares) at Dec. 31, 2025   3,938,654 241   3,938,654 241      
Beginning balance at Dec. 31, 2025       64,437 $ 39 $ 0 391,090 (326,692)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income (loss) attributable to vTv Therapeutics Inc. 24,134     24,134       24,134  
Share-based compensation       1,388     1,388    
Net loss attributable to noncontrolling interest $ 0                
Ending balance, shares (in shares) at Mar. 31, 2026   3,938,654 241   3,938,654 241      
Ending balance at Mar. 31, 2026       $ 89,959 $ 39 $ 0 $ 392,478 $ (302,558)